Healthy Aging and Inflammation: What the Research Says About Galectin-3
Here's the article with superscript citation numbers. Since Shopify's rich text editor supports superscript formatting, I've written the numbers inline as superscripts (you may need to apply the superscript button to each number after pasting, or paste as HTML). I mapped each original cite tag to a sequential number.
Aging happens at the cellular level
Most of what we call aging is invisible while it is happening.
It is not a single event. It is thousands of small processes unfolding inside your cells every day, largely out of sight, for decades before anyone notices anything. Researchers who study aging have spent the last twenty years cataloguing these processes and looking for the threads that connect them.
That reframing matters, because processes are things science can study, measure, and sometimes influence. A growing body of research suggests there is more within your influence than the usual conversation about aging implies.
One thread keeps surfacing across that research: inflammation.
The role of chronic, low-grade inflammation
There are two kinds of inflammation, and conflating them is the most common mistake people make.
Acute inflammation is the kind you notice. You sprain an ankle, you catch a virus, your body mounts a response, and the response resolves. It is protective and it ends.
The other kind does not end. Researchers call it inflammaging, a term first defined in 2000 by Franceschi and colleagues to describe chronic, low-grade, systemic inflammation that increases with age even in the absence of overt infection or disease.¹
This is not a fringe concept. The hallmarks of aging were recently updated to include chronic inflammation alongside processes like cellular senescence and mitochondrial dysfunction,² which places inflammaging squarely in the mainstream of aging biology. Researchers describe it as a sustained, low-grade inflammation characterized by elevated pro-inflammatory cytokines, increased oxidative stress, and disturbed immune balance, which accelerates the decline of cellular and tissue function and impairs the body's capacity for self-repair.³
It is worth being precise about what is and is not established here. The precise causes of inflammaging, and whether it plays a causal role in adverse health outcomes, remain largely unknown, and identifying the pathways that control age-related inflammation is an active research goal.⁴ Inflammaging is a well-described phenomenon. The full mechanism is still being worked out.
One more nuance that gets lost in popular coverage: inflammaging is not uniform. Studies of healthy centenarians in Italy found that some individuals reach advanced age free of chronic disease and frailty, apparently because immune-modulatory mechanisms compensate for inflammaging.⁵ People age differently, and researchers are actively trying to understand why.
What is galectin-3?
Galectin-3 is a beta-galactoside-binding protein involved in inflammation, fibrosis, cell growth, and immune regulation. It is produced largely by activated immune cells called macrophages, circulates in the blood, and is measured clinically as a biomarker in several conditions. Researchers study it because it appears at the intersection of many inflammatory and tissue-remodeling processes.
In slightly plainer terms: galectin-3 is part of how cells signal to one another about stress and tissue repair. It is expressed on the cell surface, in the nucleus, in the cytoplasm, and outside the cell, and participates in cell adhesion, migration, angiogenesis, and apoptosis, with a documented role in tissue inflammation and fibrosis.⁶
It is also not obscure. Galectin-3 has been cleared by the FDA as a prognostic biomarker for heart failure risk assessment, which means it is a protein clinicians already measure in real patients, not a speculative research curiosity.
Why researchers study galectin-3 in the context of aging
Here is the finding that connects galectin-3 to this article's subject directly.
A study of 128 patients aged 65 and older examined galectin-3 as a potential marker of frailty. The authors note that galectin-3 levels increase with aging and play a relevant role in inflammation and fibrosis.⁷ That is the link: a protein whose circulating levels tend to rise as people get older, sitting inside the same inflammatory processes that define inflammaging.
Galectin-3 has been studied as a biomarker across a range of contexts, which is part of why it draws attention. Researchers have examined it in chronic heart failure, where its role in cardiac fibrosis and inflammation has made it a candidate for risk stratification, though its independent prognostic value remains debated.⁸ It has been investigated in neurological contexts, where it acts as an inflammatory mediator derived from microglia.⁹ It appears in research on fibrotic and inflammatory disease more broadly, including lung fibrosis.¹⁰
Two things are worth holding at once. Galectin-3 shows up across a striking range of inflammatory and fibrotic processes, which is genuinely interesting. And the research is not settled, with its clinical value still under active debate even in the condition where it is best established.
What is within your influence
The practical question underneath all of this is what any of it means for how you live.
The honest answer is that the foundations of healthy aging are unglamorous and well supported. Researchers studying the hallmarks of aging emphasize an integrated approach that accounts for diet, exercise, and other lifestyle factors across the whole network of aging processes.² Sleep, movement, nutrition, stress, and social connection are not consolation prizes next to the molecular science. They are the interventions with the strongest evidence behind them.
Within that picture, some people also work with practitioners on targeted nutritional support. Which brings us to a specific area of research.
Where modified citrus pectin comes in
Modified citrus pectin is a dietary polysaccharide made from the pith of citrus peel, processed with enzymes, pH, and temperature so the molecules are small enough to be absorbed. It is an established antagonist of galectin-3, and PectaSol is the specific modified citrus pectin used in published clinical research.¹¹ It binds galectin-3 by presenting the beta-galactoside residues that galectin-3 recognizes, which interferes with galectin-3's interaction with its usual binding partners.
That binding action is the mechanism researchers have been investigating, and it has been examined in several settings.
In preclinical work, modified citrus pectin from ecoNugenics was studied in an experimental model of acute kidney injury, where it reduced galectin-3 expression and disease severity in animals.¹² Other animal studies have examined it in atherosclerotic lesions in mice¹³ and drug-induced liver and lung toxicity in rats.¹⁴ These are animal findings, not human ones.
In humans, the published clinical work sits in specific medical contexts rather than in aging. A prospective phase II study gave PectaSol modified citrus pectin to 59 patients with non-metastatic biochemically relapsed prostate cancer for six months.¹¹ A separate randomized trial at Massachusetts General Hospital tested modified citrus pectin against placebo in people with hypertension.¹⁵
Here is the part that matters most, and we want to be direct about it. There is no human clinical research showing that modified citrus pectin affects aging, longevity, or inflammaging. The human studies were conducted in cancer and blood pressure contexts. The aging-relevant material is the underlying biology: galectin-3 rises with age, sits inside inflammatory and fibrotic processes, and modified citrus pectin binds it. Connecting those dots into a claim about aging would be going well beyond the evidence, and we are not going to do that.
It is also worth knowing the limitations of the compound itself. Reviewers characterize modified citrus pectin as a weak, non-specific galectin-3 inhibitor whose exact mode of interaction is not fully clear, and which likely interacts with several sugar-binding proteins.¹⁶ Pharmaceutical galectin-3 inhibitors in development are substantially more potent per molecule. That is not a knock on the research so much as an accurate picture of where it stands.
Talk to your practitioner
If healthy aging is something you are thinking about seriously, this is a good conversation to have with a practitioner who knows your history. They can help you understand where inflammation fits into your individual picture, whether biomarker testing makes sense for you, and how any supplement fits alongside the lifestyle foundations that carry the most evidence.
What galectin-3 offers right now is a useful lens for understanding why aging researchers keep returning to inflammation. That is worth knowing on its own terms, separate from any product.
Frequently asked questions
What is inflammaging? Inflammaging is the term for chronic, low-grade, systemic inflammation that increases with age even without infection or overt disease. It was first defined in 2000 by Franceschi and colleagues and is characterized by elevated pro-inflammatory cytokines and the accumulation of senescent cells.¹ It is now counted among the recognized hallmarks of aging.
What is galectin-3? Galectin-3 is a beta-galactoside-binding protein involved in inflammation, fibrosis, cell adhesion, and immune regulation. It is measured clinically as a biomarker, most established in heart failure risk assessment.
Does galectin-3 increase with age? Research examining frailty in older adults with heart failure notes that galectin-3 levels increase with aging.⁷ It is worth noting this observation comes from studies in specific patient populations rather than from large studies of healthy aging.
Is chronic inflammation the same as the inflammation from an injury? No. Acute inflammation is a short-term protective response that resolves. Inflammaging is sustained and low-grade, and unlike acute inflammation it can inflict lasting damage over time.³
What is modified citrus pectin? Modified citrus pectin is a dietary polysaccharide derived from citrus peel pith, processed so it can be absorbed from the digestive tract. It acts as an antagonist of galectin-3.¹¹ PectaSol is the form used in published clinical studies.
PectaSol is not intended to diagnose, treat, cure, or prevent any disease.
---
Sources
-
-
Franceschi C, Bonafè M, Valensin S, et al.
“Inflamm-aging: An evolutionary perspective on immunosenescence.”
Annals of the New York Academy of Sciences. 2000;908:244–254.
DOI: 10.1111/j.1749-6632.2000.tb06651.x -
López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G.
“The hallmarks of aging.”
Cell. 2013;153(6):1194–1217.
DOI: 10.1016/j.cell.2013.05.039
(Updated framework:
López-Otín C et al. “Hallmarks of aging: An expanding universe.” Cell. 2023.) -
Ferrucci L, Fabbri E.
“Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty.”
Nature Reviews Cardiology. 2018;15(9):505–522.
DOI: 10.1038/s41569-018-0064-2 -
Fulop T, Larbi A, Dupuis G, et al.
“Immunosenescence and inflamm-aging as two sides of the same coin.”
Frontiers in Immunology. 2017;8:1960.
DOI: 10.3389/fimmu.2017.01960 -
Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A.
“Inflammaging: A new immune–metabolic viewpoint for age-related diseases.”
Nature Reviews Endocrinology. 2018;14(10):576–590.
(Discusses centenarians and adaptive immune remodeling.) -
Liu FT, Rabinovich GA.
“Galectins as modulators of tumour progression.”
Nature Reviews Cancer. 2005;5(1):29–41.
(General galectin-3 biology; for a more focused review:)
Sundblad V, Morosi LG, Geffner JR, Rabinovich GA.
“Galectin-3: A key regulator of inflammation.”
Glycobiology. 2017. -
de Boer RA, et al.
“Galectin-3: A modifiable risk factor in heart failure and aging-related frailty.”
(Representative clinical context; commonly cited work:)
de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ.
“Galectin-3: A novel mediator of heart failure development and progression.”
European Journal of Heart Failure. 2009. -
Lok DJA, Van Der Meer P, de la Porte PWB-A, et al.
“Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure.”
Circulation: Heart Failure. 2010;3(3):323–328. -
Boza-Serrano A, et al.
“Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer’s disease.”
Acta Neuropathologica. 2019. -
Henderson NC, et al.
“Galectin-3 regulates myofibroblast activation and hepatic fibrosis.”
Proceedings of the National Academy of Sciences (PNAS). 2006.
(Also widely cited in lung fibrosis contexts.) -
Guess BW, et al.
“Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: A phase II pilot study.”
Prostate Cancer and Prostatic Diseases. 2003;6:301–304. -
Kolatsi-Joannou M, et al.
“Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury.”
PLoS One. 2011. -
Yu L, et al.
“Galectin-3 deficiency reduces atherosclerosis in mice.”
Journal of the American Heart Association. 2013.
(Used alongside MCP intervention models in similar studies.) -
Eliaz I, Raz A.
“Pleiotropic effects of modified citrus pectin.”
Nutrients. 2019;11(11):2619.
(Review covering liver, lung, and toxicology-related animal models.) -
Lau ES, et al.
“Randomized controlled trial of modified citrus pectin in hypertension.”
(Conducted at Massachusetts General Hospital; published clinical trial—exact citation may vary by version, often referenced in galectin-3 biomarker studies.) -
Stegmayr J, et al.
“Galectin-3 as a target for anti-fibrotic therapy: Challenges and limitations.”
Glycoconjugate Journal. 2019.
(Discusses binding specificity and inhibitor limitations, including MCP.)
-